Sample size calculation for studies with grouped survival data

被引:2
作者
Li, Zhiguo [1 ]
Wang, Xiaofei [1 ]
Wu, Yuan [1 ]
Owzar, Kouros [1 ]
机构
[1] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27710 USA
关键词
grouped survival data; proportional hazards model; sample size calculation; END-POINTS; TRIALS; VACCINE; CANCER; COHORT; MODEL;
D O I
10.1002/sim.7847
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Grouped survival data arise often in studies where the disease status is assessed at regular visits to clinic. The time to the event of interest can only be determined to be between two adjacent visits or is right censored at one visit. In data analysis, replacing the survival time with the endpoint or midpoint of the grouping interval leads to biased estimators of the effect size in group comparisons. Prentice and Gloeckler developed a maximum likelihood estimator for the proportional hazards model with grouped survival data and the method has been widely applied. Previous work on sample size calculation for designing studies with grouped data is based on either the exponential distribution assumption or the approximation of variance under the alternative with variance under the null. Motivated by studies in HIV trials, cancer trials and in vitro experiments to study drug toxicity, we develop a sample size formula for studies with grouped survival endpoints that use the method of Prentice and Gloeckler for comparing two arms under the proportional hazards assumption. We do not impose any distributional assumptions, nor do we use any approximation of variance of the test statistic. The sample size formula only requires estimates of the hazard ratio and survival probabilities of the event time of interest and the censoring time at the endpoints of the grouping intervals for one of the two arms. The formula is shown to perform well in a simulation study and its application is illustrated in the three motivating examples.
引用
收藏
页码:3904 / 3917
页数:14
相关论文
共 18 条
[1]   Sample size calculation in cost-effectiveness cluster randomized trials: optimal and maximin approaches [J].
Abu Manju, Md ;
Candel, Math J. J. M. ;
Berger, Martijn P. F. .
STATISTICS IN MEDICINE, 2014, 33 (15) :2538-2553
[2]   Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study CALGB 30607 (Alliance) [J].
Baggstrom, Maria Q. ;
Socinski, Mark A. ;
Wang, Xiaofei F. ;
Gu, Lin ;
Stinchcombe, Thomas E. ;
Edelman, Martin J. ;
Baker, Sherman, Jr. ;
Feliciano, Josephine ;
Novotny, Paul ;
Hahn, Olwen ;
Crawford, Jeffrey A. ;
Vokes, Everett E. .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (05) :843-849
[3]  
Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404
[4]  
George SL, 2016, CANC CLIN TRIALS CUR
[5]   Designing follow-up times [J].
Inoue, LYT ;
Parmigiani, G .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2002, 97 (459) :847-858
[6]  
Kalbfleisch J. D., 2002, The Statistical Analysis of Failure Time Data, V2nd edition
[7]   Power of the Mantel-Haenszel and other tests for discrete or grouped time-to-event data under a chained binomial model [J].
Lachin, John M. .
STATISTICS IN MEDICINE, 2013, 32 (02) :220-229
[8]   Weighted Likelihood Method for Grouped Survival Data in Case-Cohort Studies with Application to HIV Vaccine Trials [J].
Li, Zhiguo ;
Gilbert, Peter ;
Nan, Bin .
BIOMETRICS, 2008, 64 (04) :1247-1255
[9]   SAMPLE-SIZE DETERMINATION FOR GROUPED EXPONENTIAL OBSERVATIONS - A COST FUNCTION-APPROACH [J].
LUI, KJ ;
STEFFEY, D ;
PUGH, JK .
BIOMETRICAL JOURNAL, 1993, 35 (06) :677-688
[10]   SAMPLE-SIZE DETERMINATION FOR COHORT STUDIES UNDER AN EXPONENTIAL COVARIATE MODEL WITH GROUPED DATA [J].
LUI, KJ .
BIOMETRICS, 1993, 49 (03) :773-778